Acromegaly Market Research Report- Global Forecast Till 2027

Acromegaly Market Information: By Types (Ectopic Acromegaly, Acromegaly Due to Growth Hormone), By Diagnosis (Medical Imaging, Medical Laboratory Investigations), By Treatment (Medications, Surgery, Radiation Therapy), By End Users (Hospitals, Clinics) - Global Forecast till 2027

ID: MRFR/Pharma/3020-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.


Market Scenario
Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others. The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.


The global acromegaly market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.


 


Intended Audience



  • Pharmaceutical and Biotechnological Companies

  • Medical Devices Industries

  • Research and Development (R&D) Companies

  • Hospitals and Clinics

  • Academic Institutes and Universities

Figure 1: Global Acromegaly Market, by Treatment Share, 2016 (%)
Acromegaly Market

Sources: WHO, annual reports, press release, white paper, company presentation



Segmentations
Acromegaly market is segmented on the basis of types, diagnosis, treatment, and end users.


On the basis of types, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.


On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, and others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.


On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery and transphenoidal surgery.


On the basis of end users, the market is segmented into hospitals, clinics, and others.



Regional Analysis
The Americas dominates the global acromegaly market owing to the increasing prevalence of acromegaly. According to a Health research funding organization, over 3,000 new cases of acromegaly occurs per year, with a prevalence of about 25,000 acromegaly patients in the US. Increased patient population and high per capita income have driven the growth of the market. Additionally, high healthcare expenditure, strong government support for research & development and the presence of some of the leading players have fuelled the growth of the market in this region.


Europe holds the second position in the global acromegaly market, which is followed by Asia Pacific. The presence of government support and availability of funds for research and development drive the growth of the European market. Asia Pacific is the fastest growing acromegaly market owing to the increasing population, increasing prevalence of hormonal diseases, and rapidly developing healthcare sector.


On the other hand, the Middle East & Africa owns the least share of the global market owing to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.



Key Players

Some of key the players in the market are Novartis AG (Switzerland), Aegis Therapeutics LLC (US), Chiasma Inc (US), Crinetics Pharmaceuticals Inc (US), Daewoong Pharmaceutical Co Ltd (South Korea), Peptron Inc (South Korea), Silence Therapeutics Plc (UK), Strongbridge Biopharma plc (US), Amryt Pharma plc (UK), Foresee Pharmaceuticals LLC (US), Glide Pharmaceutical Technologies Ltd (US), Ionis Pharmaceuticals Inc (US), Ipsen SA (France)



Research Methodology
global Acromegaly Market


Sources: WHO, annual reports, press release, white paper, and company presentation

 



Frequently Asked Questions (FAQ) :


Acromegaly market is projected to grow at a 5.2% CAGR between 2017- 2023.

The Americas is expected to dominate the acromegaly market.

Major end users of acromegaly market include clinics, hospitals, and others.

High surgery cost and unavailability of precise treatment are factors that may limit the acromegaly market growth.

Key players profiled in the acromegaly market include Ipsen SA (France), Ionis Pharmaceuticals Inc (US), Glide Pharmaceutical Technologies Ltd (US), Foresee Pharmaceuticals LLC (US), Amryt Pharma plc (UK), Strongbridge Biopharma plc (US), Silence Therapeutics Plc (UK), Peptron Inc (South Korea), Daewoong Pharmaceutical Co Ltd (South Korea), Crinetics Pharmaceuticals Inc (US), Chiasma Inc (US), Aegis Therapeutics LLC (US), and Novartis AG (Switzerland).

BRIEF TOC

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Acromegaly Market, by Type

6.1 Introduction

6.2 Ectopic Acromegaly

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Acromegaly due to Growth Hormone

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Others

6.4.1 Market Estimates & Forecast, 2020-2027

Chapter 7. Global Acromegaly Market, by Diagnosis

7.1 Introduction

7.2 Medical Imaging

Market Estimates & Forecast, 2020-2027

7.2.1 Radiography

7.2.2 Magnetic Resonance Imaging (MRI)

7.2.3 Nuclear Medicine

7.2.4 Ultrasound

7.2.5 Others

7.3 Medical Laboratory Investigations

Market Estimates & Forecast, 2020-2027

7.4 Others

Market Estimates & Forecast, 2020-2027

Chapter 8. Global Acromegaly Market, by Treatment

8.1 Introduction

8.2 Medications

Market Estimates & Forecast, 2020-2027

8.2.1 Somatostatin Analogues

8.2.2 Dopamine Agonists

8.2.3 Growth Hormone Receptor Antagonists

8.2.4 Others

8.3 Surgery

Market Estimates & Forecast, 2020-2027

8.3.1 Endonasal Transphenoidal Surgery

8.3.2 Transphenoidal Surgery

8.4 Radiation Diagnosis

Market Estimates & Forecast, 2020-2027

8.5 Others

Market Estimates & Forecast, 2020-2027

Chapter 9. Global Acromegaly Market, by End User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Clinics

9.2.2 Market Estimates & Forecast, 2020-2027

9.4 Others

Chapter 10. Global Acromegaly Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12. Company Profiles

12.1 Novartis AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Aegis Therapeutics LLC

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Chiasma Inc

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Crinetics Pharmaceuticals Inc

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Daewoong Pharmaceutical Co Ltd

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Silence Therapeutics Plc

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Strongbridge Biopharma plc

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13. MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Acromegaly industry

Chapter 14. Appendix

DATA TABLES

Table 1 Acromegaly Industry Synopsis, 2020-2027

Table 2 Global Acromegaly Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Acromegaly Market by Region, 2020-2027, (USD Million)

Table 4 Global Acromegaly Market by Types, 2020-2027, (USD Million)

Table 5 Global Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 6 Global Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 7 Global Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 8 North America Acromegaly Market by Types, 2020-2027, (USD Million)

Table 9 North America Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 10 North America Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 11 North America Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 12 US Market by Types, 2020-2027, (USD Million)

Table 13 US Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 14 US Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 15 US Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 16 Canada Market by Types, 2020-2027, (USD Million)

Table 17 Canada Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 18 Canada Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 19 Canada Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 20 South America Market by Types, 2020-2027, (USD Million)

Table 21 South America Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 22 South America Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 23 South America Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 24 Europe Market by Types, 2020-2027, (USD Million)

Table 25 Europe Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Europe Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 27 Europe Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 28 Western Europe Market by Types, 2020-2027, (USD Million)

Table 29 Western Europe Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 30 Western Europe Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 31 Western Europe Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 32 Eastern Europe Market by Types, 2020-2027, (USD Million)

Table 33 Eastern Europe Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 34 Eastern Europe Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 35 Eastern Europe Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 36 Asia Pacific Market by Types, 2020-2027, (USD Million)

Table 37 Asia Pacific Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 38 Asia Pacific Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 39 Asia Pacific Acromegaly Market by End Users, 2020-2027, (USD Million)

Table 40 Middle East & Africa Market by Types, 2020-2027, (USD Million)

Table 41 Middle East & Africa Acromegaly Market by Diagnosis, 2020-2027, (USD Million)

Table 42 Middle East & Africa Acromegaly Market by Treatment, 2020-2027, (USD Million)

Table 43 Middle East & Africa Acromegaly Market by End Users, 2020-2027, (USD Million)

FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Acromegaly Market

Figure 3 Segmentation Market Dynamics for Global Acromegaly Market

Figure 4 Global Acromegaly market Share, by type 2020

Figure 5 Global Acromegaly market Share, by Diagnosis 2020

Figure 6 Global Acromegaly market Share, by Treatment 2020

Figure 7 Global Acromegaly Market Share, by End Users, 2020

Figure 8 Global Acromegaly Market Share, by Region, 2020

Figure 9 North America Acromegaly Market Share, by Country, 2020

Figure 10 Europe Acromegaly Market Share, by Country, 2020

Figure 11 Asia Pacific Acromegaly Market Share, by Country, 2020

Figure 12 Middle East & Africa Acromegaly Market Share, by Country, 2020

Figure 13 Global Acromegaly Market: Company Share Analysis, 2020 (%)

Figure 14 Novartis AG: Key Financials

Figure 15 Novartis AG: Segmental Revenue

Figure 16 Novartis AG: Geographical Revenue

Figure 17 Aegis Therapeutics LLC: Key Financials

Figure 18 Aegis Therapeutics LLC: Segmental Revenue

Figure 19 Aegis Therapeutics LLC: Geographical Revenue

Figure 20 Chiasma Inc.: Key Financials

Figure 21 Chiasma Inc.: Segmental Revenue

Figure 22 Chiasma Inc.: Geographical Revenue

Figure 23 Crinetics Pharmaceuticals Inc.: Key Financials

Figure 24 Crinetics Pharmaceuticals Inc.: Segmental Revenue

Figure 25 Crinetics Pharmaceuticals Inc.: Geographical Revenue

Figure 26 Daewoong Pharmaceutical Co Ltd.: Key Financials

Figure 27 Daewoong Pharmaceutical Co Ltd.: Segmental Revenue

Figure 28 Daewoong Pharmaceutical Co Ltd.: Geographical Revenue

Figure 29 Silence Therapeutics Plc: Key Financials

Figure 30 Silence Therapeutics Plc: Segmental Revenue

Figure 31 Silence Therapeutics Plc: Geographical Revenue

Figure 32 Strongbridge Biopharma plc.: Key Financials

Figure 33 Strongbridge Biopharma plc.: Segmental Revenue

Figure 34 Strongbridge Biopharma plc.: Geographical Revenue